Insider Buying: Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Director Purchases $126,134.16 in Stock

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Director Douglas Roeder bought 22,686 shares of the stock in a transaction dated Tuesday, May 12th. The stock was purchased at an average cost of $5.56 per share, with a total value of $126,134.16. Following the completion of the purchase, the director directly owned 144,635 shares in the company, valued at approximately $804,170.60. This trade represents a 18.60% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Senseonics Holdings, Inc. Common Stock Stock Down 0.9%

NASDAQ:SENS opened at $5.77 on Friday. Senseonics Holdings, Inc. Common Stock has a 12-month low of $4.79 and a 12-month high of $12.58. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.51 and a quick ratio of 4.55. The company has a market cap of $241.19 million, a price-to-earnings ratio of -2.89 and a beta of 1.05. The business has a fifty day moving average of $6.37.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.06). Senseonics Holdings, Inc. Common Stock had a negative return on equity of 129.97% and a negative net margin of 213.87%.The company had revenue of $11.71 million during the quarter. As a group, equities research analysts expect that Senseonics Holdings, Inc. Common Stock will post -2.38 earnings per share for the current year.

Key Headlines Impacting Senseonics Holdings, Inc. Common Stock

Here are the key news stories impacting Senseonics Holdings, Inc. Common Stock this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across several future periods, including 2026 through 2030, suggesting improving expectations for Senseonics’ loss path and long-term outlook. HC Wainwright estimate revisions
• Positive Sentiment: The firm kept a Buy rating and $14 price target, indicating meaningful upside potential from recent trading levels. HC Wainwright buy rating
• Positive Sentiment: Director Douglas Roeder bought 22,686 shares at $5.56 each, a vote of confidence that investors often view as a bullish insider signal. SEC Form 4 filing
• Neutral Sentiment: Even after the estimate upgrades, analysts still expect Senseonics to remain unprofitable over the forecast period, so investors may still be waiting for clearer revenue and margin improvement.
• Negative Sentiment: HC Wainwright also cut its prior price target from $18.50 to $14.00, which shows some caution on valuation and may cap enthusiasm. Price target reduction
• Negative Sentiment: The company’s most recent earnings report missed expectations, reinforcing concerns that profitability remains distant.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Stifel Nicolaus reduced their price target on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday, May 11th. Weiss Ratings assumed coverage on Senseonics Holdings, Inc. Common Stock in a research report on Tuesday, February 17th. They issued a “sell (d-)” rating on the stock. Finally, HC Wainwright reduced their price target on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Senseonics Holdings, Inc. Common Stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC lifted its holdings in Senseonics Holdings, Inc. Common Stock by 666.7% during the second quarter. First Light Asset Management LLC now owns 35,708,124 shares of the company’s stock worth $17,011,000 after acquiring an additional 31,050,619 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Senseonics Holdings, Inc. Common Stock by 2.2% during the third quarter. Vanguard Group Inc. now owns 34,219,484 shares of the company’s stock worth $14,920,000 after acquiring an additional 749,453 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Senseonics Holdings, Inc. Common Stock by 26.6% during the second quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company’s stock worth $4,147,000 after acquiring an additional 1,828,302 shares in the last quarter. Masters Capital Management LLC lifted its holdings in Senseonics Holdings, Inc. Common Stock by 11.1% during the third quarter. Masters Capital Management LLC now owns 5,000,000 shares of the company’s stock worth $2,179,000 after acquiring an additional 500,000 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Senseonics Holdings, Inc. Common Stock by 409.0% during the third quarter. UBS Group AG now owns 4,248,519 shares of the company’s stock worth $1,852,000 after acquiring an additional 3,413,866 shares in the last quarter. 12.36% of the stock is currently owned by institutional investors.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.